Optimized Outcomes

Regardless of the ownership structure, we act with the mentality of a shareholder advocate. We serve a broad spectrum of organizations, ranging from early stage, high growth companies to well-established, multi-billion dollar global corporations.


Falcon Advises RXTransparent in its Sale to Inmar, a Portfolio Company of OMERS.

WAYNE, PENNSYLVANIA – February 11, 2020: Falcon Capital Partners, LLC (“Falcon”), a leading middle-market investment bank, is pleased to announce the sale of Forerunner Holdings, dba RXTransparent, (“RXTransparent”) to Inmar Intelligence (“Inmar”), a portfolio company of OMERS Private Equity (“OMERS”).

RXTransparent, headquartered in King of Prussia, PA, is the first and only DSCSA (Drug Supply Chain Security Act) compliance solution that provides visibility and transparency throughout the entire healthcare supply chain. Built on a modern platform with blockchain technology, the SaaS product is sold into the “last mile” pharmacy dispensing locations, facilitating the most common medication tracking scenarios from the loading dock all the way through dose.

Founded in 1980 and headquartered in Winston-Salem, North Carolina, Inmar operates intelligent commerce networks, connecting offline and online transactions in real time for the world’s largest retailers, manufacturers and trading partners across multiple industries. Inmar’s customers rely on the Company to securely manage billions of dollars in transactions across its promotions, supply chain, and healthcare platforms. In addition, Inmar’s platforms generate meaningful data and enable the Company to provide clients with actionable analytics and insights to meet the evolving needs of shoppers, patients and businesses.

The acquisition brings with it two solutions that will support Inmar Intelligence’s pharmacy clients to make pharmacy operations more efficient and compliant with two recent industry regulations: DSCSA and USP <800>. “Achieving compliance within the healthcare industry is only getting more urgent and failure to comply is not an option,” said David Mounts, Chairman and CEO of Inmar Intelligence. “Adding RXTransparent’s pharmacy compliance solutions to our already powerful healthcare platform provides our clients with an unmatched level of support to achieve and maintain compliance while saving time and protecting their staff, patients and facility.”

Falcon served as an exclusive sell-side advisor to RXTransparent. Falcon began its relationship as a strategic advisor two years ago to assist the company with the development of the business plan and investment strategy, which culminated in a successful investment round led by private individuals. Founder Dwight DeVera commented, “The Falcon team has been an outstanding partner throughout RXTransparent’s journey from providing strategic advisory services to their lead in negotiating a successful sale to Inmar. Ted and his team have provided invaluable advice and counsel which has helped RXTransparent become the success it is today.”

The terms of the transaction were not disclosed. The complete press release can be found here.

This transaction represents Falcon’s continued work in healthcare information technology (HCIT) and the second pharma HCIT transaction in the last 12 months. The Falcon deal team was led by Managing Director Ted Stack and Senior Associate Conrad Olenik. For more information please contact Ted at tstack@falconllc.com, 610-989-8901 or Conrad at colenik@falconllc.com, 610-989-8905.